CA2660703A1 - Salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide - Google Patents

Salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide Download PDF

Info

Publication number
CA2660703A1
CA2660703A1 CA002660703A CA2660703A CA2660703A1 CA 2660703 A1 CA2660703 A1 CA 2660703A1 CA 002660703 A CA002660703 A CA 002660703A CA 2660703 A CA2660703 A CA 2660703A CA 2660703 A1 CA2660703 A1 CA 2660703A1
Authority
CA
Canada
Prior art keywords
formula
compound
crystalline
salt form
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002660703A
Other languages
English (en)
French (fr)
Inventor
Xiaoming Chen
Xiao Chen
Jianguo Yin
Xiaoyong Fu
David J. Blythin
Rongze Kuang
Ho-Jane Shue
Scott Trzaska
Chee-Wah Tang
Vincenzo Liotta
Zaher Shabani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2660703(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of CA2660703A1 publication Critical patent/CA2660703A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002660703A 2006-08-14 2007-08-10 Salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide Abandoned CA2660703A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14
US60/837,661 2006-08-14
PCT/US2007/017848 WO2008021271A1 (en) 2006-08-14 2007-08-10 Salts of 5 - ( l ( s ) -amino - 2 - hydroxyethyl ) -n- [ ( 2, 4 -difluorophenyl) -methyl] - 2 - [ 8 -methoxy - 2 - (trifluoromethyl) - 5 - quinoline] - 4 - oxazolecarboxamide

Publications (1)

Publication Number Publication Date
CA2660703A1 true CA2660703A1 (en) 2008-02-21

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002660703A Abandoned CA2660703A1 (en) 2006-08-14 2007-08-10 Salts of 5-(1(s)-amino-2-hydroxyethyl)-n-[(2,4-difluorophenyl)-methyl]-2-[8-methoxy-2-(trifluoromethyl)-5-quinoline]-4-oxazolecarboxamide

Country Status (11)

Country Link
US (1) US7956189B2 (enExample)
EP (1) EP2069337A1 (enExample)
JP (3) JP2010500406A (enExample)
CN (1) CN101522671A (enExample)
AR (1) AR062373A1 (enExample)
CA (1) CA2660703A1 (enExample)
CL (1) CL2007002366A1 (enExample)
MX (1) MX2009001770A (enExample)
PE (1) PE20080424A1 (enExample)
TW (1) TW200819446A (enExample)
WO (1) WO2008021271A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
JP2015524400A (ja) * 2012-07-19 2015-08-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ９−［４−（３−クロロ−２−フルオロ−フェニルアミノ）−７−メトキシ−キナゾリン−６−イルオキシ］−１，４−ジアザ−スピロ［５．５］ウンデカン−５−オンのフマル酸塩、その薬物としての使用及び調製
HK1217439A1 (zh) 2013-01-23 2017-01-13 Aldeyra Therapeutics, Inc. 与毒性醛相关的疾病和治疗
CN118724806A (zh) 2015-08-21 2024-10-01 奥尔德拉医疗公司 氘化化合物和其用途
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
AU2019319740A1 (en) 2018-08-06 2021-03-25 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3137301A1 (en) 2019-05-02 2020-11-05 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20060241A1 (es) 2004-05-18 2006-04-01 Schering Corp 2-quinolil-oxazoles sustituidos como inhibidores de pde4

Also Published As

Publication number Publication date
PE20080424A1 (es) 2008-04-28
AR062373A1 (es) 2008-11-05
US20080108818A1 (en) 2008-05-08
MX2009001770A (es) 2009-02-25
JP2012176989A (ja) 2012-09-13
US7956189B2 (en) 2011-06-07
TW200819446A (en) 2008-05-01
WO2008021271A1 (en) 2008-02-21
EP2069337A1 (en) 2009-06-17
JP2010500406A (ja) 2010-01-07
CL2007002366A1 (es) 2008-03-14
CN101522671A (zh) 2009-09-02
JP2013032394A (ja) 2013-02-14

Similar Documents

Publication Publication Date Title
US7956189B2 (en) Maleate, tosylate, fumarate and oxalate salts of 5-(1-(S)-amino-2-hydroxyethyl)-N-[(2,4-difluorophenyl)-methy]-2-[8-methoxy-2-(triflouromethy)-5-quinoline]-4-oxazolecarboxamide and preparation process therefore
US7956048B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
US20250179048A1 (en) Polymorphs of [2-(1h-indol-3-yl)-1h-imidazol-4-yl](3,4,5-trimethoxyphenyl)methanone and its salts
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
RU2335502C2 (ru) Полиморфы пирролзамещенных 2-индолиноновых ингибиторов протеинкиназы
JP7472024B2 (ja) ファソラセタムの固体形態
AU2004215407B2 (en) Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors
JP7152122B2 (ja) エダラボン塩
TW201111387A (en) Novel crystal form of tricyclic benzopyran compound and production method thereof
TW202021960A (zh) 貝前列素-314d單水合物晶體及其製備方法
JP2024525254A (ja) ウロデシン塩
CN105523994B (zh) 甲磺酸洛美他派晶型iii
CN114258395A (zh) 一种酯化合物的晶型及其制备方法
TW202334098A (zh) 吡嗪類衍生物的鹽的晶型及其製備方法
CN116120380A (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
TW201636346A (zh) 二－匹多莫德苄乙二胺及其固體型
WO2013181384A1 (en) Solid state forms of aleglitazar sodium
HK1086486B (en) Polymorphs of pyrrole substituted 2-indolinone protein kinase inhibitors

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150303